Cerebrovascular events primary prevention in metabolic syndrome patients
Aim. To study effects of therapy with bisoprolol (Concor®) and deproteinized hemoderivate (Actovegin®) on circadian blood pressure profile (CBPP), carbohydrate, lipid metabolism, and cerebral perfusion in patients with metabolic syndrome (MS) and mild arterial hypertension (AH). Material and methods...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«SILICEA-POLIGRAF» LLC
2006-04-01
|
Series: | Кардиоваскулярная терапия и профилактика |
Subjects: | |
Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1127 |
Summary: | Aim. To study effects of therapy with bisoprolol (Concor®) and deproteinized hemoderivate (Actovegin®) on circadian blood pressure profile (CBPP), carbohydrate, lipid metabolism, and cerebral perfusion in patients with metabolic syndrome (MS) and mild arterial hypertension (AH). Material and methods. The study included 30 patients with mild AH and MS: 15 participants received Concor®, 15 - Concor® and Actovegin®, for 12 weeks. All individuals underwent clinical and laboratory examination, as well as cerebral perfusion assessment by single-photon emission computer tomography. Results. In both groups, therapy was associated with significant BP decrease and CBPP normalization, together with neutral metabolic effect. At baseline, cerebral perfusion was reduced in all patients. Actovegin® treatment substantially improved cerebral perfusion. Conclusion. In MS patients, Actovegin® facilitated cerebral perfusion improvement, with neutral metabolic effect. |
---|---|
ISSN: | 1728-8800 2619-0125 |